Skip to content

Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome

Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00403689
Enrollment
11
Registered
2006-11-27
Start date
2006-11-30
Completion date
2008-03-31
Last updated
2013-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Keywords

Increased non-specific inflammatory markers

Brief summary

Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides. Previous studies indicate that the intake of insoluble dietary fiber is strongly associated with reduced risk of type 2 diabetes and cardiovascular disease. However, the mechanisms leading to this phenomenon are largely unknown. There are close relations between metabolic and inflammatory pathways, and a number of hormones, cytokines, signal proteins, bioactive lipids, and transcription factors have been shown to be involved in both systems. Beta-D-glucans have been suggested to play a role as so called biological response modifiers. Studies in animals indicate that even small doses of (1,3),(1,6)-beta-D-glucan may have beneficial effects on immune activity, i.e., by reducing the secretion of inflammatory factors. The investigators hypothesize that the intake of isolated (1,3), (1,6)-beta-D-glucan from bakers yeast improves inflammatory makers and insulin-sensitivity in overweight subjects with increased C-reactive protein concentrations at baseline.

Interventions

DIETARY_SUPPLEMENTBeta-D-Glucan

1,5 g Beta-D-Glucan daily

DIETARY_SUPPLEMENTplacebo

1.5 g waxy maize starch daily

Sponsors

Danone Research Foundation
CollaboratorUNKNOWN
Leiber Company
CollaboratorUNKNOWN
German Institute of Human Nutrition
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects with normal glucose tolerance (NGT) * Impaired glucose tolerance (IGT) * Impaired fasting glucose (IFG)

Exclusion criteria

* Any severe cardiac disease * Liver * Kidney diseases * Type 1 or type 2 diabetes * Chronical and acute inflammatory diseases * Lipid lowering drugs * Cortisone * Antibiotics * Non-steroidal antiinflammatory drugs * Including low dose acetylsalicylic acid

Design outcomes

Primary

MeasureTime frame
Beta-D-glucan induced changes in inflammatory markers, adipokines, and gut hormones. Changes in insulin-sensitivity.3 days

Secondary

MeasureTime frame
Altered gene expression in adipose tissue if changes in primary outcome measures are shown.3 days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026